Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.66, while Novo Nordisk A/S trades at $44.73 (market cap $200.69B). The key difference: Novo Nordisk A/S pays a 3.98% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $63.98 |
52-Week Low | $11.58 | $35.29 |
Market Cap | — | $200.69B |
Enterprise Value | — | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.82, down 1.23% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF generates consistent weekly dividends but faces structural limitations in capturing Nvidia's full upside potential. Recent analyst downgrades highlight concerns about declining volatility reducing option income effectiveness and potential NAV erosion despite the attractive 39.7% annualized distribution rate.
The outlook remains cautious as NVDY's strategy sacrifices long-term capital appreciation for income generation. While weekly distributions provide cash flow, the fund's structural cap on upside participation and reliance on Nvidia's volatility create headwinds. Investors seeking pure Nvidia exposure may find better alternatives, while income-focused investors should weigh the high distribution rate against potential principal erosion.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
